作者
Michael Höpfner, Detlef Schuppan, Hans Scherübl
发表日期
2008/1/1
来源
World journal of gastroenterology: WJG
卷号
14
期号
1
页码范围
1
出版商
Baishideng Publishing Group Inc
简介
Growth factors and their corresponding receptors are commonly overexpressed and/or dysregulated in many cancers including hepatocellular cancer (HCC). Clinical trials indicate that growth factor receptors and their related signalling pathways play important roles in HCC cancer etiology and progression, thus providing rational targets for innovative cancer therapies. A number of strategies including monoclonal antibodies, tyrosine kinase inhibitors (“small molecule inhibitors”) and antisense oligonucleotides have already been evaluated for their potency to inhibit the activity and downstream signalling cascades of these receptors in HCC. First clinical trials have also shown that multi-kinase inhibition is an effective novel treatment strategy in HCC. In this respect sorafenib, an inhibitor of Raf-, VEGF-and PDGF-signalling, is the first multi-kinase inhibitor that has been approved by the FDA for the treatment of …
引用总数
学术搜索中的文章
M Höpfner, D Schuppan, H Scherübl - World journal of gastroenterology: WJG, 2008